当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.

Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.

Abstract：

OBJECTIVES:Follicular lymphoma (FL) is generally considered an indolent disorder but a significant subset of patients shows a worse outcome. Aim of this study was to validate the FLIPI score in an independent series of follicular lymphoma patients and to correlate prognostic categories with the period of diagnosis and the use of anthracycline. METHODS:We evaluated the clinical characteristics, prognostic stratification, and outcome of 338 patients with follicular lymphoma consecutively diagnosed and followed at our Institution between 1975 and 2002. RESULTS:The distribution of patients within the prognostic categories of the IPI and FLIPI score, while confirming the indolent outcome of follicular lymphoma, shows that a subset of patients has a worse prognosis. With the IPI score, 62% of patients are in the low risk, 26% in the low-intermediate, and 12% in the high (high-intermediate+high) risk group. With the FLIPI score, 48% of patients are categorized as low risk, 31% as intermediate risk, and 21% as poor risk. With the IPI score, median OS is 17.3 years for the low risk; 6.3 for the intermediate risk, and 5.2 years for the high risk group (p=0.0004). With the FLIPI system, median OS is 15.5 years for the low risk, 8.3 years for the intermediate risk, and 5.2 for the poor risk group (p=0.0002). Prognostic scores were calculated also after dividing patients according to the time of diagnosis: in three periods (before 1987, between 1988 and 1997, and from 1998), as well as in two periods (before and after 1998). In all the periods studied survival of patients classified according to IPI and FLIPI categories was significantly different. CONCLUSION:This study shows in an independent series that the FLIPI score is a reproducible prognostic index of clinical utility for the initial assessment of patients with follicular lymphoma.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Arcaini L,Colombo N,Passamonti F,Burcheri S,Orlandi E,Brusamolino E,Della Porta M,Rumi E,Montanari F,Pascutto C,Paulli M,Lazzarino M

doi

10.1016/j.leukres.2005.07.006

keywords:

subject

Has Abstract

pub_date

2006-03-01 00:00:00

pages

277-82

issue

3

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(05)00288-2

journal_volume

30

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling.

    abstract：:Chemotherapy resistance has been considered as a major problem for multiple myeloma (MM) treatment and bone marrow microenvironment plays a crucial role in the MM progression and chemoresistance. Recent studies reported that bone marrow mesenchymal stem cells derived from MM patients (MM-MSCs) revealed various charact...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.07.002

    authors： Yang H,Zheng Y,Zhang Y,Cao Z,Jiang Y

    更新日期：2017-09-01 00:00:00

  • Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome.

    abstract：:Quantitative differences in HLe-1 expression were studied on normal lymphocytes and lymphoblasts of patients with acute lymphoblastic leukemia (ALL). A relationship was found between quantitative antigen expression and therapeutic outcome. Alterations in fluorescence intensity (FI) were demonstrated using quantitative...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90110-x

    authors： Caldwell CW,Patterson WP,Hakami N

    更新日期：1987-01-01 00:00:00

  • Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.

    abstract：BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.01.009

    authors： Dholaria BR,Ayala E,Sokol L,Nishihori T,Chavez JC,Hussaini M,Kumar A,Kharfan-Dabaja MA

    更新日期：2018-04-01 00:00:00

  • Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

    abstract：:The association between seven polymorphisms in the genes hOCT1 and MDR1, encoding for imatinib transporter proteins, and the response to imatinib 400mg/daily was investigated in 65 patients newly diagnosed with chronic-phase chronic myeloid leukemia. The AA genotype at the rs6935207 hOCT1 polymorphic locus was not det...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.12.004

    authors： Maffioli M,Camós M,Gaya A,Hernández-Boluda JC,Alvarez-Larrán A,Domingo A,Granell M,Guillem V,Vallansot R,Costa D,Bellosillo B,Colomer D,Cervantes F

    更新日期：2011-08-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Role of interleukin-2 in depressed T-cell mitogenesis after allogeneic marrow transplantation in man.

    abstract：:Proliferative responses of mononuclear cells in liquid cultures to phytohemagglutinin, a T-cell mitogen, are depressed for a long time after allogeneic marrow transplantation. We examined the role of interleukin-2, a lymphokine important in T-cell mitogenesis, in the impaired phytohemagglutinin responses early after m...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90081-x

    authors： Elfenbein GJ,Adams JS,Bellis MM,Santos GW,Smith KA

    更新日期：1984-01-01 00:00:00

  • Effect of pulsed magnetic fields on leukemia-prone AKR mice. No-effect on mortality through five generations.

    abstract：:Leukemia-prone AKR mice were exposed twice a week to a 6 mT, 12 Hz or 460 Hz pulsed magnetic field for 30 min. If we take into account the five consecutive generations of mice, the above exposure actually took place in utero and, or during their life span. There was no difference in the incidence of leukemia or in the...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90165-p

    authors： Bellossi A

    更新日期：1991-01-01 00:00:00

  • The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells.

    abstract：:The MTT cell viability assay is widely used in determining drug sensitivity profiles for patients with hematological malignancies and in primary screening of potential chemotherapeutic drugs. Because the multidrug resistance (MDR) phenotype is associated with these malignancies, and since many vital dyes are effluxed ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(92)90114-m

    authors： Marks DC,Belov L,Davey MW,Davey RA,Kidman AD

    更新日期：1992-12-01 00:00:00

  • Serum double monoclonal components and hematological malignancies: only a casual association? Review of 34 cases.

    abstract：:A double monoclonal component (MC) detected in the serum and/or urine represents a very rare occurrence (2-6% of monoclonal gammopathies). In this study, we report 34 patients with double serum MCs, focusing on the associated diseases. The diagnosis was made using high-resolution serum protein electrophoresis and immu...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.05.008

    authors： Guastafierro S,Ferrara MG,Sica A,Parascandola RR,Santangelo S,Falcone U

    更新日期：2012-10-01 00:00:00

  • What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?

    abstract：:We report the case of an elderly patient affected by Philadelphia positive Acute Lymphoblastic Leukaemia (Ph(+) ALL) who developed meningeal leukaemia during imatinib monotherapy, despite bone marrow molecular remission. Aggressive central nervous system (CNS)-directed therapy in combination with continued imatinib tr...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.018

    authors： Mele G,Pinna S,Melpignano A,Romano A,Brocca MC,Coppi MR,Quarta G

    更新日期：2007-10-01 00:00:00

  • Functional interleukin-2 receptor on a Tac negative human leukaemia T-cell line.

    abstract：:Cell line PER-423 was derived from the cells of a patient with an immature acute T-lymphoblastic leukaemia and the growth of this human cell line is strictly dependent on interleukin-2 (IL-2). PER-423 cells express the p75 (beta) subunit of the IL-2 receptor (IL-2R beta), while the p55 chain (IL-2R alpha) is not detec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(93)90141-7

    authors： Kees UR,Ford J,Peroni SE,Ranford PR

    更新日期：1993-01-01 00:00:00

  • Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.

    abstract：:The methylation inhibitor decitabine (DAC) has great therapeutic value for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, DAC monotherapy is associated with relatively low rates of overall response and complete remission. Previous studies have shown promising results for combination treatmen...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.02.002

    authors： Geng S,Yao H,Weng J,Tong J,Huang X,Wu P,Deng C,Li M,Lu Z,Du X

    更新日期：2016-05-01 00:00:00

  • Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.

    abstract：:A novel bivalent single chain fusion protein, Bic3, was assembled consisting of the catalytic and translocation domains of diphtheria toxin (DT(390)) fused to two repeating sFv molecules recognizing human CD3 epsilon of the human T-cell receptor. Historically, problems with these constructs include low yield, toxicity...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.08.006

    authors： Vallera DA,Todhunter D,Kuroki DW,Shu Y,Sicheneder A,Panoskaltsis-Mortari A,Vallera VD,Chen H

    更新日期：2005-03-01 00:00:00

  • The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.

    abstract：INTRODUCTION:The seven in absentia homolog 2 (SIAH2) protein plays a significant role in human cancer by regulating hypoxia-inducible factor-a (HIF-1α); however, its role in T-cell acute lymphoblastic leukemia (T-ALL) is less clear. METHODS:Immunofluorescence evaluation of SIAH2 protein expression and location were co...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.01.013

    authors： Chen H,Wang N,Yang G,Guo Y,Shen Y,Wang X,Zhang P,Xu Y

    更新日期：2016-03-01 00:00:00

  • Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.

    abstract：:FLT3 is a receptor tyrosine kinase involved in the survival of hematopoietic stem cells, and mutations of FLT3 have been reported to be of prognostic significance. This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute. FLT3 int...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.11.006

    authors： Kang HJ,Hong SH,Kim IH,Park BK,Han KS,Cho HI,Shin HY,Ahn HS

    更新日期：2005-06-01 00:00:00

  • Reversing the multidrug resistance in acute leukemia: until the leukemia initiating cell?

    abstract：:Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characterized by a CD34+CD38- phenot...

    journal_title：Leukemia research

    pub_type： 评论,社论

    doi：10.1016/j.leukres.2008.09.022

    authors： Costello RT

    更新日期：2009-06-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract：:We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00135-5

    authors： Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期：1998-01-01 00:00:00

  • Properties of lymphocyte 5'nucleotidase in normal subjects and patients with chronic lymphocytic leukemia.

    abstract：:Heterogeneity for 5'nucleotidase has been demonstrated in chronic lymphocytic leukemia [12]. The enzyme is not detectable in the lymphocytes from the majority of patients with this disorder, but normal and even supranormal levels are found in some cases [17]. In the present studies, the properties of this ecto-nucleot...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(82)90026-1

    authors： Conklyn MJ,Silber R

    更新日期：1982-01-01 00:00:00

  • The role of hematopoietic cell transplantation in adult ALL: clinical equipoise persists.

    abstract：:Adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) may be treated either with ongoing systemic chemotherapy or with allogeneic hematopoietic cell transplantation (alloHCT). Despite the presence of phase III trials to support clinical decision-making, we hypothesized that physicians who tr...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.10.021

    authors： Paulson K,Szwajcer D,Raymond CB,Seftel MD

    更新日期：2014-02-01 00:00:00

  • Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.

    abstract：:Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristin...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.08.016

    authors： Miyashita K,Tomita N,Taguri M,Suzuki T,Ishiyama Y,Ishii Y,Nakajima Y,Numata A,Hattori Y,Yamamoto W,Miyazaki T,Tachibana T,Takasaki H,Matsumoto K,Hashimoto C,Takemura S,Yamazaki E,Fujimaki K,Sakai R,Motomura S,Ishi

    更新日期：2015-08-29 00:00:00

  • The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

    abstract：:Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated wi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.02.002

    authors： Salar A,Haioun C,Rossi FG,Duehrsen U,Pettengell R,Johnsen HE,Jaeger U,Verhoef G,Schwenkglenks M,Bacon P,Bendall K,Lugtenburg PJ

    更新日期：2012-05-01 00:00:00

  • Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.

    abstract：BACKGROUND:Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. F...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.01.002

    authors： Xiao D,Shi Y,Fu C,Jia J,Pan Y,Jiang Y,Chen L,Liu S,Zhou W,Zhou J,Tao Y

    更新日期：2016-03-01 00:00:00

  • Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.

    abstract：:This is the case report of a 47-year-old woman referred to our institution due to acute liver failure related to imatinib, who was submitted to a successful liver transplantation. Nilotinib was safely used post-transplant. ...

    journal_title：Leukemia research

    pub_type： 信件

    doi：10.1016/j.leukres.2009.06.012

    authors： Perini GF,Santos FP,Funke V,Ruiz J,Neto BH,Hamerschlak N

    更新日期：2009-12-01 00:00:00

  • Identification of interleukin 6 as a synergistic factor for the differentiation-inducing effect of TNF on leukemic ML-1 cells.

    abstract：:Recombinant TNF was capable of inducing differentiation of human leukemic ML-1 cells in the monocytic pathway. Recombinant interleukin 6 did not have the activity but it could significantly increase the activity of recombinant TNF. Both of these molecules were found to play a similar role in PWM-induced conditioned me...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90010-7

    authors： Samal B,Stearns G,Crandall C,Arakawa T,Boone T

    更新日期：1990-01-01 00:00:00

  • Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

    abstract：:Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in treatment decisions. We examined 280 newly diagnosed higher-risk elderly MDS patients paired with ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.05.012

    authors： Caocci G,Voso MT,Angelucci E,Stauder R,Cottone F,Abel G,Nguyen K,Platzbecker U,Beyne-Rauzy O,Gaidano G,Invernizzi R,Molica S,Criscuolo M,Breccia M,Lübbert M,Sanpaolo G,Buccisano F,Ricco A,Palumbo GA,Niscola P,Zhan

    更新日期：2015-08-01 00:00:00

  • Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.

    abstract：:Bcr-Abl tyrosine kinase inhibitor induces apoptosis and erythroid differentiation of K562 cells. During this erythroid differentiation, c-Myc and cyclin D1 transcripts are transiently downregulated. Accordingly, we studied the effect of cyclin D1 overexpression on erythroid differentiation. After treatment with 250 nM...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2003.10.022

    authors： Kawano T,Horiguchi-Yamada J,Saito S,Iwase S,Furukawa Y,Kano Y,Yamada H

    更新日期：2004-06-01 00:00:00

  • Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.

    abstract：:To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2011.05.015

    authors： Latagliata R,Breccia M,Castagnetti F,Stagno F,Luciano L,Gozzini A,Ulisciani S,Cavazzini F,Annunziata M,Sorà F,Rossi AR,Pregno P,Montefusco E,Abruzzese E,Crisà E,Musto P,Tiribelli M,Binotto G,Occhini U,Feo C,Vigner

    更新日期：2011-09-01 00:00:00

  • Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

    abstract：:Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.03.015

    authors： Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

    更新日期：2015-07-01 00:00:00

  • Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

    abstract：:Homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high remission rate and provide a survival advantage in acute myeloid leukemia (AML). To investigate whether HAA is an ideal induction regimen for t(8;21)AML, we retrospectively analyzed the data of 140 patients from the las...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.02.012

    authors： Zhu HH,Jiang H,Jiang Q,Jia JS,Qin YZ,Huang XJ

    更新日期：2016-05-01 00:00:00

  • Palmitic acid, verified by lipid profiling using secondary ion mass spectrometry, demonstrates anti-multiple myeloma activity.

    abstract：:Recent studies indicate that lipid metabolic changes affect the survival of multiple myeloma (MM) cells. Time-of-flight secondary ion mass spectrometry (TOF-SIMS), an imaging mass spectrometry technique, is used to visualize the subcellular distribution of biomolecules including lipids. We therefore applied this metho...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.02.011

    authors： Nagata Y,Ishizaki I,Waki M,Ide Y,Hossen MA,Ohnishi K,Miyayama T,Setou M

    更新日期：2015-06-01 00:00:00